These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22990084)

  • 41. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics.
    Caro JJ
    Pharmacoeconomics; 2016 Jul; 34(7):665-72. PubMed ID: 26961779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adding Events to a Markov Model Using DICE Simulation.
    Caro JJ; Möller J
    Med Decis Making; 2018 Feb; 38(2):235-245. PubMed ID: 28675959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
    Soto J
    Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical management and burden of prostate cancer: a Markov Monte Carlo model.
    Sanyal C; Aprikian A; Cury F; Chevalier S; Dragomir A
    PLoS One; 2014; 9(12):e113432. PubMed ID: 25474006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a decision-analytic model of stroke care in the United States and Europe.
    Chambers MG; Koch P; Hutton J
    Value Health; 2002; 5(2):82-97. PubMed ID: 11918824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging methods in economic modeling of imaging costs and outcomes a short report on discrete event simulation.
    Hollingworth W; Spackman DE
    Acad Radiol; 2007 Apr; 14(4):406-10. PubMed ID: 17368208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Decision Analysis and Markov Modeling for Surgeons: An Introductory Overview.
    Hogendoorn W; Moll FL; Sumpio BE; Hunink MG
    Ann Surg; 2016 Aug; 264(2):268-74. PubMed ID: 26756750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The quality of three decision-analytic diabetes models: a systematic health economic assessment.
    Becker C; Langer A; Leidl R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):751-62. PubMed ID: 22098291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
    Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
    Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ISPOR-SMDM task force's recommendations for good modeling practices-reply to letter to the editor by Corro Ramos.
    Caro JJ; Eddy DM; Hollingworth W; Tsevat J; McDonald KM; Wong JB; Briggs AH; Siebert U; Kuntz KM
    Value Health; 2013; 16(6):1108. PubMed ID: 24041365
    [No Abstract]   [Full Text] [Related]  

  • 53. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A mathematical approach for evaluating Markov models in continuous time without discrete-event simulation.
    van Rosmalen J; Toy M; O'Mahony JF
    Med Decis Making; 2013 Aug; 33(6):767-79. PubMed ID: 23715464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Scalable approximate policies for Markov decision process models of hospital elective admissions.
    Zhu G; Lizotte D; Hoey J
    Artif Intell Med; 2014 May; 61(1):21-34. PubMed ID: 24791675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process.
    Li F; Jörg F; Li X; Feenstra T
    Pharmacoeconomics; 2022 Nov; 40(11):1015-1032. PubMed ID: 36100825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.
    Reed Johnson F; Lancsar E; Marshall D; Kilambi V; Mühlbacher A; Regier DA; Bresnahan BW; Kanninen B; Bridges JF
    Value Health; 2013; 16(1):3-13. PubMed ID: 23337210
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.